Julian Chavarriaga (@chavarriagaj) ranks #17 among US gu cancer KOLs on X in 2026, by engagement from fellow physicians. 20 physicians shared, quoted or replied to their posts this year. Most-discussed trials in 2026: KEYNOTE-B15 / EV-304, KEYNOTE-905 / EV-303, VOLGA.
At a Glance
- 12 posts naming a trial in 2026
- 11 trials discussed by name
- GU Cancer: US #17 · 20 physicians engaged
This Month
What Julian Chavarriaga has posted in the last 30 days. Updated November 10, 2026.
#ESMO26 From transforming the management of VHL-associated RCC to expanding treatment options in advanced ccRCC, HIF-2α inhibition has come a long way. An excellent tour de force by Dr. Albiges on how far we've come and what lies ahead: 🔹 LITESPARK-005: Established belzutifan as a later-line option in advanced ccRCC. 🔹 LITESPARK-011: Belzutifan + lenvatinib improved PFS and ORR; OS remains immature. 🔹 Adjuvant setting: Belzutifan + pembrolizumab has demonstrated improved DFS. 🔹 Next frontier: LITESPARK-034 and other trials are evaluating the optimal TKI partner. 📌The biology is compelling, but optimal sequencing, combination partners, resistance, and patient selection remain unresolved. @UroToday @myESMO
#ESMO26 A subgroup analysis of the phase III POTOMAC trial in papillary-only high-risk NMIBC: 📌Papillary-only: DFS HR 0.56; 48-month DFS 84% vs 74% 📌T1 subgroup: DFS HR 0.48; 48-month DFS 85% vs 73% 📌High-risk recurrence: 13% vs 20% in papillary-only disease 📌 Fewer early high-risk events, BCG-unresponsive recurrences and cystectomies 📌The trade-off: Grade 3–4 AEs were 34% vs 16%. @UroToday @myESMO
#ESMO26 Dr. Michiel van der Heijden discussed the implications of VOLGA alongside KEYNOTE-905 and KEYNOTE-B15: 🔹 EV + durvalumab doublet: EFS HR 0.51; OS HR 0.58, a 42% reduction in the hazard of death. 🔹 Triplet (+ tremelimumab): EFS HR 0.61; OS not yet significant. More toxicity, without a demonstrated advantage from CTLA-4 blockade. 🔹 Crucial difference: VOLGA used only 3 neoadjuvant cycles of EV, followed by RC and adjuvant durvalumab, without adjuvant EV. 🔹 The unresolved question: Which patients need adjuvant therapy? pCR is informative, but does not guarantee eradication of micrometastatic disease. 🚨Key message: The doublet is the regimen most likely to move forward. The next breakthrough may come from response-adapted treatment, not adding another drug. @UroToday @myESMO
#ESMO26 VOLGA: Could just 3 cycles of neoadjuvant EV redefine treatment for cisplatin-ineligible MIBC? @tompowles1 presented landmark phase III results: 🔹 EV + durvalumab doublet: EFS HR 0.51; OS HR 0.58 (42% lower risk of death) 🔹 pCR: 45% vs 10% with surgery alone 🔹 Triplet (+ tremelimumab): EFS HR 0.61; OS not yet significant 🔹 ctDNA: ~78% positive at baseline; ~60% clearance by postsurgery assessment. 🔹 Safety: Grade 3–4 AEs ~30% with the doublet, only 11% interruption of EV 🚨The big message: Just 3 neoadjuvant cycles of EV + durvalumab, followed by cystectomy and adjuvant durvalumab alone, deliver a substantial survival benefit. A new standard for cisplatin-ineligible MIBC? 🚨Concomitant publication @NEJM @UroToday @myESMO
#ESMO26 The prespecified HRQoL analysis from phase III KEYNOTE-B15/EV-304 was presented: 🔹 Efficacy: EV+P improved EFS (HR 0.53) and OS (HR 0.65) vs neoadjuvant gemcitabine/cisplatin. 🔹 Global QoL at postsurgery week 42: −1.58 vs −2.43 points, with no meaningful between-group difference. 🔹 Physical function: −5.42 vs −6.28 points; role function: −9.56 vs −9.35 points. 🔹 Sexual function: The largest and most persistent deterioration (−15.13 vs −14.82 points), regardless of treatment. @UroToday @myESMO
#ESMO26 Can molecular profiling identify who benefits most from perioperative durvalumab in MIBC? Exploratory genomic/transcriptomic analyses from NIAGARA. 🔹 TP53alt in 50% of tumors, co-occurred with RB1, while mutually exclusive with FGFR3. 🔹ERCC2-mutated tumors achieved 75% pCR across treatment arms. 🔹 EFS benefit: TMB-high HR 0.44; TP53-mutated HR 0.51; FGFR3-mutated HR 0.24. 🔹 Immune-enriched subtypes: Basal-squamous HR 0.47; luminal-infiltrated HR 0.67. 🔹 Higher T-effector infiltration and IFNγ signaling were associated with greater benefit. @UroToday @myESMO
Who Amplifies Julian Chavarriaga
Physicians who reposted Julian Chavarriaga’s trial posts most often in 2026.
2026 Rankings
| List | US rank | Global rank | Physicians engaged | Physician engagements | |
|---|---|---|---|---|---|
| GU Cancer | #17 | — | 20 | 31 | Full ranking |
Trials Julian Chavarriaga Discussed in 2026
| Trial | Posts | Rank among physicians posting | Latest |
|---|---|---|---|
| KEYNOTE-B15 / EV-304 | 3 | #12 of 44 | Oct 24, 2026 |
| KEYNOTE-905 / EV-303 | 2 | #6 of 16 | Oct 24, 2026 |
| VOLGA | 2 | #18 of 57 | Oct 24, 2026 |
| LITESPARK-011 | 1 | #17 of 37 | Oct 25, 2026 |
| POTOMAC | 1 | #5 of 17 | Oct 24, 2026 |
| NIAGARA | 1 | #14 of 32 | Oct 24, 2026 |
| KEYNOTE-564 | 1 | #5 of 16 | Oct 23, 2026 |
| LITESPARK-022 | 1 | #13 of 40 | Oct 23, 2026 |
| TROPHY-U-01 | 1 | #5 of 10 | Oct 23, 2026 |
| KEYNOTE-866 | 1 | #9 of 26 | Oct 23, 2026 |
| ENERGIZE (CA017-078) | 1 | #6 of 17 | Oct 23, 2026 |
Julian Chavarriaga on KEYNOTE-B15 / EV-304
#ESMO26 Dr. Michiel van der Heijden discussed the implications of VOLGA alongside KEYNOTE-905 and KEYNOTE-B15: 🔹 EV + durvalumab doublet: EFS HR 0.51; OS HR 0.58, a 42% reduction in the hazard of death. 🔹 Triplet (+ tremelimumab): EFS HR 0.61; OS not yet significant. More toxicity, without a demonstrated advantage from CTLA-4 blockade. 🔹 Crucial difference: VOLGA used only 3 neoadjuvant cycles of EV, followed by RC and adjuvant durvalumab, without adjuvant EV. 🔹 The unresolved question: Which patients need adjuvant therapy? pCR is informative, but does not guarantee eradication of micrometastatic disease. 🚨Key message: The doublet is the regimen most likely to move forward. The next breakthrough may come from response-adapted treatment, not adding another drug. @UroToday @myESMO
#ESMO26 The prespecified HRQoL analysis from phase III KEYNOTE-B15/EV-304 was presented: 🔹 Efficacy: EV+P improved EFS (HR 0.53) and OS (HR 0.65) vs neoadjuvant gemcitabine/cisplatin. 🔹 Global QoL at postsurgery week 42: −1.58 vs −2.43 points, with no meaningful between-group difference. 🔹 Physical function: −5.42 vs −6.28 points; role function: −9.56 vs −9.35 points. 🔹 Sexual function: The largest and most persistent deterioration (−15.13 vs −14.82 points), regardless of treatment. @UroToday @myESMO
#ESMO26 Exploratory ctDNA findings from phase III KEYNOTE-B15, comparing perioperative EV+pembrolizumab vs cisplatin/gemcitabine. Key findings: 📌Presurgical ctDNA clearance: 82.1% vs 66.7% 📌24-month EFS after ctDNA clearance: 81.1% vs 63.2% 📌Persistent ctDNA positivity: 24-month EFS only ~33–35% 📌Postsurgical ctDNA positivity: Only 10% event-free at 24 months in either arm 📌Presurgical ctDNA-negative patients: pCR 72.4% vs 43.7% @UroToday @myESMO
Julian Chavarriaga on KEYNOTE-905 / EV-303
#ESMO26 Dr. Michiel van der Heijden discussed the implications of VOLGA alongside KEYNOTE-905 and KEYNOTE-B15: 🔹 EV + durvalumab doublet: EFS HR 0.51; OS HR 0.58, a 42% reduction in the hazard of death. 🔹 Triplet (+ tremelimumab): EFS HR 0.61; OS not yet significant. More toxicity, without a demonstrated advantage from CTLA-4 blockade. 🔹 Crucial difference: VOLGA used only 3 neoadjuvant cycles of EV, followed by RC and adjuvant durvalumab, without adjuvant EV. 🔹 The unresolved question: Which patients need adjuvant therapy? pCR is informative, but does not guarantee eradication of micrometastatic disease. 🚨Key message: The doublet is the regimen most likely to move forward. The next breakthrough may come from response-adapted treatment, not adding another drug. @UroToday @myESMO
#ESMO26 How much does each drug contribute to perioperative EV + pembrolizumab in MIBC? 🚨A 3-arm analysis of KEYNOTE-905/EV-303 (N=255). EV+P vs P alone vs surgery: 🔹 3-year EFS: 69.5% vs 49.6% vs 37.4% 🔹 pCR: 58.8% vs 25.3% vs 10.3% 🔹 Pathologic downstaging: 65.9% vs 33.7% vs 14.9% 🔹 EFS HR vs surgery: 0.40 with EV+P; 0.71 with P alone 📌The efficacy gradient suggests both EV and pembrolizumab contribute to the combination's activity, with substantially greater benefit from EV+P. 📌Important caveat: descriptive, ad hoc analysis without formal statistical testing. @UroToday @myESMO
Julian Chavarriaga on VOLGA
#ESMO26 Dr. Michiel van der Heijden discussed the implications of VOLGA alongside KEYNOTE-905 and KEYNOTE-B15: 🔹 EV + durvalumab doublet: EFS HR 0.51; OS HR 0.58, a 42% reduction in the hazard of death. 🔹 Triplet (+ tremelimumab): EFS HR 0.61; OS not yet significant. More toxicity, without a demonstrated advantage from CTLA-4 blockade. 🔹 Crucial difference: VOLGA used only 3 neoadjuvant cycles of EV, followed by RC and adjuvant durvalumab, without adjuvant EV. 🔹 The unresolved question: Which patients need adjuvant therapy? pCR is informative, but does not guarantee eradication of micrometastatic disease. 🚨Key message: The doublet is the regimen most likely to move forward. The next breakthrough may come from response-adapted treatment, not adding another drug. @UroToday @myESMO
#ESMO26 VOLGA: Could just 3 cycles of neoadjuvant EV redefine treatment for cisplatin-ineligible MIBC? @tompowles1 presented landmark phase III results: 🔹 EV + durvalumab doublet: EFS HR 0.51; OS HR 0.58 (42% lower risk of death) 🔹 pCR: 45% vs 10% with surgery alone 🔹 Triplet (+ tremelimumab): EFS HR 0.61; OS not yet significant 🔹 ctDNA: ~78% positive at baseline; ~60% clearance by postsurgery assessment. 🔹 Safety: Grade 3–4 AEs ~30% with the doublet, only 11% interruption of EV 🚨The big message: Just 3 neoadjuvant cycles of EV + durvalumab, followed by cystectomy and adjuvant durvalumab alone, deliver a substantial survival benefit. A new standard for cisplatin-ineligible MIBC? 🚨Concomitant publication @NEJM @UroToday @myESMO
Julian Chavarriaga on LITESPARK-011
#ESMO26 From transforming the management of VHL-associated RCC to expanding treatment options in advanced ccRCC, HIF-2α inhibition has come a long way. An excellent tour de force by Dr. Albiges on how far we've come and what lies ahead: 🔹 LITESPARK-005: Established belzutifan as a later-line option in advanced ccRCC. 🔹 LITESPARK-011: Belzutifan + lenvatinib improved PFS and ORR; OS remains immature. 🔹 Adjuvant setting: Belzutifan + pembrolizumab has demonstrated improved DFS. 🔹 Next frontier: LITESPARK-034 and other trials are evaluating the optimal TKI partner. 📌The biology is compelling, but optimal sequencing, combination partners, resistance, and patient selection remain unresolved. @UroToday @myESMO
Julian Chavarriaga on POTOMAC
#ESMO26 A subgroup analysis of the phase III POTOMAC trial in papillary-only high-risk NMIBC: 📌Papillary-only: DFS HR 0.56; 48-month DFS 84% vs 74% 📌T1 subgroup: DFS HR 0.48; 48-month DFS 85% vs 73% 📌High-risk recurrence: 13% vs 20% in papillary-only disease 📌 Fewer early high-risk events, BCG-unresponsive recurrences and cystectomies 📌The trade-off: Grade 3–4 AEs were 34% vs 16%. @UroToday @myESMO
Julian Chavarriaga on NIAGARA
#ESMO26 Can molecular profiling identify who benefits most from perioperative durvalumab in MIBC? Exploratory genomic/transcriptomic analyses from NIAGARA. 🔹 TP53alt in 50% of tumors, co-occurred with RB1, while mutually exclusive with FGFR3. 🔹ERCC2-mutated tumors achieved 75% pCR across treatment arms. 🔹 EFS benefit: TMB-high HR 0.44; TP53-mutated HR 0.51; FGFR3-mutated HR 0.24. 🔹 Immune-enriched subtypes: Basal-squamous HR 0.47; luminal-infiltrated HR 0.67. 🔹 Higher T-effector infiltration and IFNγ signaling were associated with greater benefit. @UroToday @myESMO
Julian Chavarriaga on KEYNOTE-564
#ESMO26 How much benefit could adjuvant pembrolizumab + belzutifan provide over surveillance in high-risk ccRCC? An indirect comparison using reconstructed survival data from KEYNOTE-564 and LITESPARK-022 (N=2,835). 📌DFS: HR 0.55 (95% CI 0.45–0.69) 📌 24-month DFS: 79.4% vs 67.8% with placebo 📌Absolute DFS gain: 11.6% 📌OS: HR 0.56 (95% CI 0.35–0.89), an early exploratory signal @UroToday @myESMO
Julian Chavarriaga on LITESPARK-022
#ESMO26 How much benefit could adjuvant pembrolizumab + belzutifan provide over surveillance in high-risk ccRCC? An indirect comparison using reconstructed survival data from KEYNOTE-564 and LITESPARK-022 (N=2,835). 📌DFS: HR 0.55 (95% CI 0.45–0.69) 📌 24-month DFS: 79.4% vs 67.8% with placebo 📌Absolute DFS gain: 11.6% 📌OS: HR 0.56 (95% CI 0.35–0.89), an early exploratory signal @UroToday @myESMO
Julian Chavarriaga’s Most-Engaged Posts in 2026
Their own 2026 posts that fellow physicians reposted most, quoted word for word.
#ESMO26 Can we preserve the bladder with EV + P in MIBC? @tompowles1 presented the TiP: EV-209, a phase II trial exploring bladder preservation without planned RC or RT: 📌N≈240, global, single-arm study 📌 Patients eligible for but declining radical cystectomy 📌 EV+P for 4 cycles, followed by MRI/CT, cystoscopy with biopsy/TURBT, and urine cytology 📌 Patients achieving cCR continue treatment (up to 9 EV and 17 pembrolizumab cycles) 📌 Co-primary endpoints: cCR rate and 2-year bladder-intact EFS among responders 📌 Exploratory ctDNA/utDNA MRD analyses @UroToday @myESMO
#ESMO26 A multicenter study (n=671) exploring the clinical and molecular drivers of PSA ≤0.2 ng/mL was presented: 📌65.2% achieved a deep PSA response 📌Median CRPC-free survival: 88 vs 13.3 months 📌Median OS: 83.5 vs 31.5 months 📌Nonresponders showed enrichment of cell-cycle, chromosomal instability, DNA-repair and neuroendocrine programs 📌Deep responders had greater AR activity and enrichment of SPOP mutations 🚨Failure to achieve deep PSA suppression may reflect aggressive tumor biology, not simply inadequate treatment intensity. @UroToday @myESMO
#ESMO26 Does earlier ARPI increase the risk of neuroendocrine transformation in prostate cancer? A post-hoc analysis from ENZAMET (n=1,125; median follow-up 8.4 years). 📌Treatment-emergent SCNEPC: 1.7% overall 📌 Enzalutamide vs conventional NSAA: 2.7% vs 0.7% (IRR 3.3; p=0.04) 📌Median time to SCNEPC: 3.1 years 📌Median OS after transformation: only 9 months 📌Baseline neuroendocrine signatures: 70% vs 43% among patients who did vs did not develop SCNEPC 🏴Despite the higher observed incidence, enzalutamide substantially prolonged CRPC-free survival (5.8 vs 1.8 years). **Only 19 events: interpret the incidence difference cautiously. Association does not establish causation. @UroToday @myESMO
#ESMO26 Nearly 1 in 3 patients alive at 7 years with EV+pembrolizumab in cisplatin-ineligible la/mUC - Mature EV-103 data (N=121; median follow-up 64.2 months). 🔹 ORR 66.9%; median DOR 29.6 months 🔹 41% of responders maintained response at 4 years 🔹 Median OS 27.7 months; 7-year OS 28.2% 🔹 Grade ≥3 TRAEs 64.5%; discontinuation of either agent 50.4% 🔹 No new safety signals A remarkable long-term survival tail in cisplatin-ineligible la/mUC, reinforcing EV+P as 1L SOC @UroToday @myESMO
#ESMO26 Excellent presentation by @yujimiura5 on 3 critical barriers to ADC efficacy in RCC: 🔹 Delivery: Heterogeneous perfusion, limited vascular permeability, and the binding-site barrier restrict intratumoral penetration. 🔹 Targeting: Spatial heterogeneity in antigen expression across tumor and stromal compartments limits effective targeting. 🔹 Payload: Most RCC ADC trials have shown ORRs <10%, with toxicity narrowing the therapeutic window. 📌The future of ADCs in RCC may depend less on finding another antigen and more on delivering the right payload to the right compartment. @UroToday @myESMO